Phase 2
N=24
Aerosol Inhalation Treatment for Dyspnea
Healthy · Dyspnea
Bottom Line
View on ClinicalTrials.gov: NCT01440764 ↗Enrolled (actual)
24
Serious AEs
0.0%
Results posted
Jun 2017
Primary outcome: Primary: Subject Rating of Breathing Discomfort (Dyspnea) — 20; 20; 16; 17 units on a scale — p=0.99
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Furosemide (Drug); Saline (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Beth Israel Deaconess Medical Center
- Primary completion
- Apr 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Subject Rating of Breathing Discomfort (Dyspnea) |
20; 20; 16; 17; 13 | 0.99 |
| SECONDARY Multidimensional Dyspnea Profile |
8.0; 6.4; 5.5; 2.5; 7.4; 6.2 | — |
| SECONDARY Urine Output |
1069; 1320; 500; 474; 1556 | .0006 sig |
Summary
The purpose of this protocol is to develop and test optimal delivery of aerosol furosemide, a treatment that has the potential to significantly improve symptom management and enhance the quality of care for patients with intractable dyspnea.
Eligibility Criteria
Inclusion Criteria
- Healthy
Exclusion Criteria
- Unstable heart or circulation disease
- Stroke
- Seizure disorder
- Severe migraine headaches
- Liver or kidney disease
- Adrenal gland problem (Pheochromocytoma)
- Nerve problems that may affect your breathing sensation
- Brain cancer
- Drug or alcohol problem
- Systemic lupus erythematosis (SLE)
- High levels of depression, panic disorder, or other significant mental health problems
- Serious ongoing pain
- Pregnant
- Under 18 years old
- Not Fluent in English
Data sourced from ClinicalTrials.gov (NCT01440764). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.